State Street’s ABVC BioPharma ABVC Stock Holding History

State Street’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$70.6K	Hold	72,800	–	–	﹤0.01%	4084
2025 Q4	$155K	Hold	72,800	–	–	﹤0.01%	3957
2025 Q3	$221K	Buy	72,800 +59,900	+464%	+$184K	﹤0.01%	3883
2025 Q2	$28.7K	Hold	12,900	–	–	﹤0.01%	4167
2025 Q1	$13.7K	Hold	12,900	–	–	﹤0.01%	4240
2024 Q4	$7.61K	Hold	12,900	–	–	﹤0.01%	4284
2024 Q3	$8.82K	Hold	12,900	–	–	﹤0.01%	4269
2024 Q2	$9.98K	Buy	+12,900	New	+$13.2K	﹤0.01%	4322

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

State Street's ABVC Position: Q1 2026 in Review

State Street held its ABVC BioPharma (ABVC) position steady in Q1 2026 at 72,800 shares worth $70.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4084.

State Street first reported a position in ABVC in Q2 2024 and has held it in 8 quarters since. The position peaked at $221K in Q3 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

State Street held 72,800 shares of ABVC BioPharma worth $70.6K as of Q1 2026.
State Street left its ABVC BioPharma share count unchanged in Q1 2026.
ABVC BioPharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4084 holding.
State Street first reported a position in ABVC BioPharma in Q2 2024 and has held it in 8 quarters since.
State Street's ABVC BioPharma position peaked at $221K in Q3 2025.
13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.